Item 8.01 Other Events.
On June 1, 2021, Alkermes plc issued a press release announcing that the U.S.
Food and Drug Administration has approved LYBALVITM (olanzapine and samidorphan)
for the treatment of adults with schizophrenia and for the treatment of adults
with bipolar I disorder, as a maintenance monotherapy or for the acute treatment
of manic or mixed episodes, as monotherapy or an adjunct to lithium or
valproate. The press release is attached hereto as Exhibit 99.1 and is
incorporated by reference in this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by Alkermes plc dated June 1, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses